Michaela Wendeler, PhD

Director

AstraZeneca

Antibody Drug Conjugates

Matthew Kennedy

Director of Process Engineering, BioProcess Specialist, Senior Associate

CRB

Simon Keen

Scientific Leadership Team, Cell Line Development

Abzena

Anthony S. Lubiniecki, ScD

Consultant (Retired from Janssen)

A L Associates, LLC

Martin Vanderlaan, PhD

Retired/Consulting

Vanderlaan Consulting

Andreas Unsöld

Head of Cell Culture Media Development

Boehringer Ingelheim GmbH

Advanced Cell Culture Performance by Rational Media Design Based on in Depth Process Understanding

Abstract Bio
Advanced Cell Culture Performance by Rational Media Design Based on in Depth Process Understanding

Monoclonal antibodies are the leading class of biopharmaceuticals. These products are mainly produced in processes with CHO cells. A robust cell culture media platform becomes key to develop an efficient and robust production process. A comprehensive screening was performed to detect substances with the potential to improve the cell culture performance without impacting the media stability. Nineteen substances with potential effects on cysteine metabolism, cell cycle, reactive oxygen scavenger, histone deacetylase inhibitor, or intracellular cAMP were spiked to the standard fed-batch process in different concentrations. Especially substances impacting the cysteine metabolism showed the ability to prolong specific productivity and viability during the last days of the fed-batch process. The intracellular data revealed a metabolic understanding of the connection between cysteine concentration and detox pathways. Additional optimization experiments focusing on the cysteine metabolism showed a sweet spot with an increased process performance (viability and titer) without negatively affecting PQ and media stability. Among the high number of media components, cysteine is of particular interest as it plays a pivotal role in achieving prolonged cell viability and high product concentrations. Furthermore, it also has a high impact on PQ, media reactivity, and stability.

REV 011223
Andreas Unsöld

Andreas holds a degree in Food Technology from the University of Applied Sciences of Weihenstephan, Germany. After his studies he began his career in the areas of product development as well as development of functional food ingredients for the dairy industry.

In 2010 he joined Boehringer Ingelheim as a Team Leader and Senior Scientist in the Cell Culture Process Development and Clinical Supply Unit. Here he gained a lot of experience in the field of cell culture media development and processing of biopharmaceuticals for clinical studies under cGMP.

Since 2017 Andreas has headed BI´s Cell Culture Media Development Group with a strong focus on media formulation development for CHO, HEK, and EB66, scale-up, and liquid media/raw material characterization strategies.

REV 011223